Precision Medicine: A 62-Asset Test Of Whether The Vertex Model Travels Beyond Oncology
In Vivo has identified 62 non-oncology precision medicine assets currently undergoing clinical trials, with gene therapy being the predominant intervention. This analysis explores whether the successful Vertex Pharmaceuticals model, known for its precision medicine approach in oncology, can be effectively applied to other therapeutic areas. The article examines the implications of this finding for the broader life sciences industry.
Vertex Pharma stock pre-market at EUR 450.78: plus 0.37 percent
Vertex Pharma stock is trading at EUR 450.78 pre-market, marking a 0.37 percent increase from its previous close. This rise follows the company's recent announcement on September 22, 2026, detailing positive Phase 2b AMPLIFIED study results for inaxaplin in APOL1-mediated kidney disease. Vertex Pharma also confirmed completion of enrollment for its Phase 2/3 AMPLITUDE trial, with interim data expected in early 2027.
Vertex Pharma stock posts Q2 growth after crossing 200-day line
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion, a 12.5% increase year-over-year, and adjusted EPS of $4.73, both exceeding analyst estimates. The stock closed at $504.73 on October 2, 2026, above its 200-day moving average. The company's kidney disease pipeline, particularly the inaxaplin program, is a key focus for future growth beyond its cystic fibrosis franchise, with interim Phase 2/3 AMPLITUDE trial results expected in early 2027.
Vertex Pharma reports results and Vertex Pharma stock costs EUR 449.10 versus EUR 448.93
Vertex Pharmaceuticals (VRTX) stock was trading at EUR 449.10 in weekend trading on October 3, 2026, a slight increase from EUR 448.93. The company previously announced positive inaxaplin results from its Phase 2b AMPLIFIED study on September 22, 2026, showing a significant reduction in urine albumin to creatinine ratio in patients with APOL1-mediated kidney disease. Vertex anticipates sharing interim analysis results from its Phase 2/3 AMPLITUDE trial in early 2027.
Law firm probes adequacy of $150 per share Arcosa sale to CRH
Kahn Swick & Foti, LLC is investigating the proposed $150 per share all-cash sale of Arcosa, Inc. to CRH, examining if the consideration and negotiation process adequately protected shareholder interests. The firm encourages shareholders who believe the offer undervalues the company to contact them. This investigation aims to determine if the transaction terms were fair and if Arcosa's board fulfilled its fiduciary duties to maximize shareholder value.
Halper Sadeh LLC Investigates Arcosa, Crinetics Pharmaceuticals, and Leggett & Platt Over Proposed Sale Transactions
Halper Sadeh LLC is investigating Arcosa, Inc., Crinetics Pharmaceuticals, Inc., and Leggett & Platt, Incorporated for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed sale transactions. The firm is concerned that shareholders may not be receiving fair value or adequate disclosures, and that insiders could benefit disproportionately. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief for affected shareholders.
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
This article compares the competitive advantages and investment potential of Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN), two leading biotech companies. Vertex has built its moat through dominance in cystic fibrosis and is now expanding into other therapeutic areas, while Regeneron's strength lies in its scientific research engine that consistently produces new medicines. Despite different strategies, both companies face challenges in pipeline diversification and patent expirations, with their valuations reflecting investors' current perceptions of these moats.
Stifel reiterates Amylyx stock rating on avexitide confidence
Stifel reiterated a Buy rating and a $45.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) after hosting the company's Co-CEOs to discuss avexitide. Management expressed confidence in the Phase 3 data for avexitide and its commercial opportunity for post-bariatric hypoglycemia, with an NDA submission planned for Q4 2026. Other firms like Guggenheim, H.C. Wainwright, and Mizuho have also raised their price targets for Amylyx following positive LUCIDITY trial results showing a 55% reduction compared to placebo.
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
This article identifies three top gene therapy stocks—Vertex Pharmaceuticals (VRTX), Exelixis (EXEL), and Regeneron Pharmaceuticals (REGN)—that balance high upside potential with financial discipline, appealing to investors seeking growth in the biotechnology sector amidst rising borrowing costs. It highlights their revenue streams, market values, and specific treatments, while also addressing potential risks and future growth drivers for each company. The article emphasizes that these selections are part of a broader screener for biotech firms with compelling narratives.
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know
Vertex Pharmaceuticals Inc. (VRTX) saw its stock price drop by 3.21% due to macroeconomic headwinds like elevated treasury yields and investor scrutiny over its recent acquisition of Crinetics Pharmaceuticals. Technical indicators show a sell signal and an oversold condition, while fundamental analysis highlights risks such as cystic fibrosis market saturation, challenges in non-CF product launches, and rising operating expenses. Analysts have an average price target of $571.93, but revised earnings estimates suggest a cautious outlook.
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
Mergers and acquisitions slowed significantly in the third quarter of 2026 compared to Q2, with just under $30 billion across 22 transactions. Despite the overall slowdown, Vertex Pharmaceuticals made one of the year's largest deals by acquiring Crinetics Pharmaceuticals for an estimated $8.8 billion, expanding into specialty endocrinology. Eli Lilly was the most active acquirer in Q3, striking two deals and bringing its year-to-date total to 11 deals worth $31.7 billion.
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics, a clinical-stage biotechnology company, announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. Manning brings over 25 years of global biopharmaceutical experience, including leadership roles in commercialization and product launches at companies like Soleno Therapeutics and PharmaEssentia Corporation. Her expertise is expected to be invaluable as Unicycive advances its lead investigational treatment, oxylanthanum carbonate, towards potential approval and prepares for commercial-stage growth.
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts
Argus has lowered its target price for BioMarin Pharmaceutical Inc. (BMRN) to $70.00 from its current price of $60.00. BioMarin is a global biotechnology company specializing in therapies for rare genetic diseases. The report was published on September 23, 2026.
Exelixis, Inc. (EXEL) Stock forecasts
Argus has raised its target price for Exelixis, Inc. (EXEL) to $64.00, with the biopharmaceutical firm currently trading at $58.84. Exelixis specializes in discovering, developing, and commercializing cancer treatments. The report was issued on September 23, 2026.
Vertex Pharmaceuticals stock holds at EUR 464.53 as UBS lifts target
UBS has raised its price target for Vertex Pharmaceuticals to USD 615.00 from USD 585.00, maintaining a Buy rating, driven by promising kidney disease drug trial data. Vertex Pharmaceuticals (VRTX) stock was trading at EUR 464.53, up 0.02% at Lang & Schwarz, following a strong Q2 2026 revenue of USD 3.33 billion. The company's pipeline, particularly the inaxaplin treatment, and its financial performance are key factors in the revised outlook.
TG Therapeutics, Inc. (TGTX) Stock forecasts
Argus has lowered its target price for TG Therapeutics, Inc. (TGTX) to $58.00, according to a report published on September 16, 2026. The biopharmaceutical company, which focuses on treatments for B-cell diseases, is currently trading at $55.78. The report provides an earnings estimate and a summary of the company's profile.
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?
Travere Therapeutics (TVTX) recently secured a patent extension for its drug FILSPARI, now protected until October 2037 for focal segmental glomerulosclerosis. Despite mixed short-term stock performance, the company shows strong long-term sentiment and is considered 19% undervalued by many, with a fair value pegged at $74.14. However, a different valuation perspective, using sales multiples, suggests the stock might be richly priced compared to peers, indicating less room for error if the FILSPARI thesis faces challenges.
Valneva SE (OTC: INRLF) Stock Price, News & Analysis
Valneva SE (OTC: INRLF) is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases. The company offers vaccines like IXIARO and DUKORAL, and has a pipeline including candidates for Lyme disease, chikungunya, and Zika virus. Financial data and peer comparisons are provided, highlighting the company's revenue, net income, and market capitalization, along with an AI summary of its growth potential and inherent risks.
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly outperformed the market over the last decade, with an average annual return of 19.81%. An initial investment of $100 in VRTX stock 10 years ago would now be worth $606.90. This demonstrates the substantial impact of compounded returns on investment growth over time.
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam Therapeutics has filed a lawsuit against Chinese biotech YolTech Therapeutics and its U.S. partner Serapha Bio, claiming that an experimental treatment was developed using stolen trade secrets. Beam alleges that a former scientist, Zi Jun “Emma” Wang, secretly founded YolTech while still employed at Beam and filed patent applications based on Beam's confidential information. Serapha Bio, which licensed the therapy from YolTech, denies the allegations.
UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating
UBS has increased its price target for Vertex Pharmaceuticals (VRTX) to $615 from $585, while reiterating a Buy rating on the stock. This adjustment reflects continued confidence in the pharmaceutical company's prospects.
Vertex Pharmaceuticals Price Target Raised to $615.00/Share From $585.00 by UBS
UBS has increased its price target for Vertex Pharmaceuticals (VRTX) to $615.00 per share from the previous $585.00. This adjustment comes amidst ongoing analyst evaluations of the pharmaceutical company's financial prospects and market performance. The updated target suggests a positive outlook from the firm regarding Vertex's stock valuation.
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
Novo Nordisk is set to acquire ex-China rights to Hengrui Pharma's preclinical GLP-1/GIP dual receptor agonist, HRS-1596, for an upfront payment of $300 million and potential milestone payments up to $2.6 billion. The drug, designed for once-weekly oral dosing, aims to treat obesity, Type 2 diabetes, and other metabolic diseases, offering a potentially more convenient alternative to existing treatments. This deal is part of Novo's strategy to strengthen its pipeline and address investor concerns following recent challenges.
Vertex Pharmaceuticals Incorporated (VRTX) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding Vertex Pharmaceuticals (VRTX). It covers several articles from various financial news sources discussing VRTX's stock performance, kidney disease pipeline advancements, and analyst opinions. The compilation also includes performance overview data, comparing VRTX's returns against the S&P 500 benchmark.
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
Vertex Pharmaceuticals' positive Phase 2 data for APOL1 inhibition in kidney disease validates a significant market, creating a "significant positive readthrough" for Maze Therapeutics (MAZE). Truist reiterated a Buy rating on Maze, seeing blockbuster potential for its MZE829 despite development lags compared to Vertex's inaxaplin. While Vertex solidifies its renal disease expansion, Maze, with substantial cash reserves, is positioned to capitalize on this validated target but faces risks from competitive timing and cash burn.
VRTX Maintains Buy Rating by UBS -- Price Target Raised to $615
UBS has maintained a Buy rating on Vertex Pharmaceuticals (VRTX) and increased its price target from $585 to $615, indicating confidence in the company's growth trajectory and market position, especially in cystic fibrosis treatment. GuruFocus assesses VRTX as 0.9% undervalued with a strong GF Score™ of 87/100, reflecting robust financial health and profitability, despite mixed guru activity and insider selling. Investors are advised to consider the company's strong fundamentals and growth prospects.
Vertex Pharmaceuticals stock last trades at USD 526.66 on September 28, 2026
Vertex Pharmaceuticals stock closed at USD 526.66 on Nasdaq on September 28, 2026, marking a slight increase from its previous close. The company recently reported positive Phase 2b AMPLIFIED study results for inaxaplin in treating AMKD, showing significant reduction in urine albumin to creatinine ratio in certain patient cohorts. Additionally, Vertex completed its acquisition of Crinetics Pharmaceuticals, adding new assets like PALSONIFY and atumelnant to its portfolio.
UBS raises Vertex stock price target to $615 on kidney drug trial
UBS has increased its price target for Vertex Pharmaceuticals (NASDAQ:VRTX) to $615 from $585, maintaining a Buy rating. This adjustment is based on anticipated Phase III data in early 2027 for the company's APOL1 kidney disease treatment, inaxaplin, which UBS sees as a significant catalyst. The firm estimates the APOL1-mediated kidney disease market for the severe, primary AMKD population could be worth $2 billion to $3 billion.
Vertex Pharmaceuticals stock draws attention after kidney data
Vertex Pharmaceuticals (VRTX) stock is gaining attention after new data on its investigational kidney disease treatment, inaxaplin, showed a significant reduction in kidney biomarkers. While revenue for Q2 2026 beat expectations, EPS slightly missed. JPMorgan has reaffirmed an "Overweight" rating and raised its price target to USD 560.00, with the stock currently trading below this target and its 52-week high, indicating potential for growth.
Insmed (INSM) Could Be 40% Undervalued On FDA Priority Review News
Insmed (INSM) has received FDA Priority Review for its supplemental New Drug Application for ARIKAYCE, leading to speculation that the stock is 40% undervalued despite recent short-term share price drops. The company's fair value is estimated at $197.14 against a current close of $117.83, driven by a strong pipeline and upcoming catalysts like the U.S. launch of brensocatib. However, the article also notes a high P/S ratio, suggesting investors are already paying a premium based on future earnings potential.
Sarepta Therapeutics (SRPT) Falls As Patent Settlement Tests The Undervalued Narrative
Sarepta Therapeutics (SRPT) experienced a 7.1% share price drop following a sector-wide biotech selloff and a major patent litigation settlement, pushing its stock to $18.39. Despite a 90-day return of 9.14%, the stock is down 11.03% over the past week. Analysts currently value SRPT at $21.65, suggesting it is 15% undervalued, but its future depends on pipeline development and resolution of gene therapy safety concerns and administrative delays.
Telix Pharmaceuticals Ltd (TLX) Stock Price, Quote, News & History
This article provides a comprehensive overview of Telix Pharmaceuticals (TLX), including its current stock price, key statistics, recent news, financial data, and analyst trends. Telix Pharmaceuticals, operating in the healthcare and biotechnology sector, specializes in developing radiopharmaceuticals for cancer management. The company recently made headlines with a $1.65 billion acquisition of ITM Isotope to build a radiopharma powerhouse.
Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds
A Delaware federal court has ruled that generic drugmakers Teva Pharmaceuticals and Apotex Inc. do not infringe patents held by Vanda Pharmaceuticals for its sleep drug Hetlioz. This decision allows Teva and Apotex to potentially market generic versions of the medication without facing patent infringement claims from Vanda. The ruling is a significant development in the pharmaceutical industry for these companies.
Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close
Gilead Sciences (NASDAQ: GILD) shares closed at $149.69 on September 25, 2026, marking a 1.11% decline, underperforming the Nasdaq Composite. The stock's performance on the day saw it open at $150.88 and reach a high of $152.975 before closing at its session low. Gilead has a dividend payment of $0.82 per share scheduled for September 29, 2026, while analysts have raised their FY2027 EPS estimate for the company.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. (VRTX) rose 1.17% to $522.38 on Thursday, outperforming the broader stock market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marked the fourth consecutive day of gains for the stock.
Vertex Pharmaceuticals stock tracks kidney pipeline progress
Vertex Pharmaceuticals (VRTX) stock is being tracked by investors due to its kidney pipeline progress, specifically the positive Phase 2b AMPLIFIED study results for inaxaplin, which showed a significant reduction in urine albumin to creatinine ratio in patients with APOL1-mediated kidney disease. Despite narrowly missing Q2 2026 adjusted EPS estimates, the company's revenue growth of 12.5% provides strong operational support. Vertex expects interim analysis results for its pivotal AMPLITUDE program in early 2027, which will be a key factor in the stock's valuation.
Did Early Trial Results Just Shift Disc Medicine (IRON) Stock Narrative?
Disc Medicine (IRON) recently announced positive early Phase 2 trial results for DISC-3405 in polycythemia vera, which showed improved iron regulation and reduced need for phlebotomy. This development strengthens Disc Medicine's investment narrative, focusing on real-world patient outcomes in hematology, alongside its other active program, selcodebart, for myelofibrosis. Despite these clinical successes, the company remains unprofitable and will need to finance its capital-intensive pipeline, making trial progression and funding access critical risk factors.
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity
Canaccord Genuity analyst Whitney Ijem maintained a Hold rating on Vertex Pharmaceuticals (VRTX) with a price target of $442.00, citing her expertise in the Healthcare sector. Vertex Pharmaceuticals also received a Hold rating from Stifel Nicolaus, while Barclays maintained a Buy rating. The company reported strong financial results for the quarter ending June 30, with revenues of $3.33 billion and a net profit of $1.1 billion.
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)
Analysts have issued neutral ratings for Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV), with both stocks receiving "Hold" recommendations from various firms. Stifel Nicolaus maintained a Hold on VRTX, despite a "Strong Buy" consensus among analysts, while Bank of America Securities also gave ROIV a "Hold" rating, though it also holds a "Strong Buy" consensus. The article details the price targets and analyst success rates for both companies.
Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript
This article provides the Q2 2026 earnings call transcript for Vertex Pharmaceuticals (VRTX), which took place on August 3, 2026. The transcript lists the company participants including the CEO, CFO, and other executives, as well as analysts from various financial institutions. It details the attendees of the call where the company's financial performance and future outlook were likely discussed.
Learn Why The Bull Case For Insmed Stock Could Change Following Priority Review Acceptance
Insmed recently received Priority Review acceptance from the FDA for its ARIKAYCE supplemental New Drug Application for MAC lung disease, backed by strong Phase 3b ENCORE data. This development positions ARIKAYCE as a potential earlier line treatment and strengthens Insmed's rare disease portfolio. While ARIKAYCE's progress diversifies revenue, the company's near-term upside still heavily relies on the timely FDA review and commercial success of brensocatib for bronchiectasis.
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race
The global autologous hematopoietic stem cell gene therapy market is projected to grow significantly, reaching $13.44 billion by 2030 from $5.23 billion in 2025, driven by advancements in gene-editing, increased investment in rare disease treatments, and personalized therapies. Key growth factors include commercialization of gene-editing therapies, regulatory approvals, adoption of personalized medicine, and infrastructure investments. North America was the largest regional market in 2025, with Asia-Pacific expected to be the fastest-growing region.
Vertex Pharmaceuticals Incorporated (VRTX) Options Chain - Yahoo Finance
This page provides options chain data for Vertex Pharmaceuticals Incorporated (VRTX) on Yahoo Finance. It displays real-time stock price information and options data, though it currently shows no available calls or puts. The page also includes related tickers for similar companies.
Why is Maze Therapeutics stock climbing today?
Maze Therapeutics stock rose today after CIBC initiated coverage with an Outperformer rating and a $50 price target. The positive sentiment was further boosted by encouraging data from competitor Vertex Pharmaceuticals' kidney disease program, which validated the broader therapeutic approach Maze's lead compound uses. This combination of analyst confidence and sector-specific positive news drove the stock higher despite a flat broader market.
Vertex reports results from Phase IIb AMPLIFIED trial for AMKD
Vertex Pharmaceuticals announced positive results from its Phase IIb AMPLIFIED trial for inaxaplin, treating APOL1-mediated kidney disease (AMKD) in patients with modest proteinuria and type 2 diabetes. The drug demonstrated significant reductions in proteinuria and was well-tolerated across both cohorts. These findings support the potential for inaxaplin as a treatment targeting the underlying cause of AMKD, with further data expected from the pivotal AMPLITUDE study in early 2027.
Top 10: Chief Digital Officers in Healthcare
This article lists the top 10 Chief Digital Officers (CDOs) in the healthcare industry, ranked by the revenue of their respective organizations. These executives, from companies like Cigna, Roche, and Vertex, are driving digital transformation, AI adoption, and data strategies to modernize patient experience and drug development. The list highlights their significant roles in an evolving technological landscape within healthcare.
TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating
TD Cowen has increased its price target for Vertex Pharmaceuticals (VRTX) to $550 from $525, while reiterating a "Buy" rating. The company currently has an average overweight rating and a mean price target of $574.78 across analysts. Access to the full MT Newswires article requires a premium subscription.
Vertex Pharma stock gains 3 percent ahead of the open
Vertex Pharma stock (VRTX) gained 3 percent ahead of the market open on September 23, 2026, following positive AMPLIFIED study results for its kidney-disease treatment, inaxaplin. The company reported a 42.7 percent reduction in a proteinuria measure in one patient group, and BMO Capital reiterated an Outperform rating with a USD 600 price target. Interim data from the Phase 2/3 AMPLITUDE trial is expected in early 2027.
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2b AMPLIFIED Study Of Inaxaplin And Completes Enrollment In The Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals announced positive results from its Phase 2b AMPLIFIED study of inaxaplin for APOL1-mediated kidney disease (AMKD). The drug, administered as a 45 mg once-daily dose, was found to be generally safe and well-tolerated, with all adverse events being mild or moderate. Additionally, Vertex has completed enrollment for its Phase 2/3 AMPLITUDE study, which will further assess inaxaplin's impact on kidney function and proteinuria in AMKD patients.
Vertex’s midstage data amplify kidney disease market opportunity
Vertex Pharmaceuticals announced positive phase 2b data for its kidney disease drug, inaxaplin, in patients with APOL1-mediated kidney disease (AMKD) and modest proteinuria, as well as those with Type 2 diabetes. These new findings suggest a significant expansion of the potential patient population beyond the current pivotal trial, potentially adding 100,000 patients in the U.S. and Europe. The company plans to discuss these results with regulators and expects interim data from its pivotal Amplitude trial early next year, which could lead to accelerated FDA approval.
